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Abstract
Background: The Tientsin Albino 2 (TA2) mouse is an inbred strain originating from the Kunming strain. It has a
high incidence of spontaneous breast cancer without the need for external inducers or carcinogens. Until now, the
mechanism of carcinogenesis has remained unclear. In this study, we investigate differential gene expression,
especially the expression of decorin, EGFR and cyclin D1, during mammary gland epithelial cell carcinogenesis in
TA2 mice.
Methods: Gene expression profiles of spontaneous breast cancer and matched normal mammary gland tissues in
TA2 mice were ascertained using an Affymetrix Mouse 430 2.0 array. Twelve mammary tissue samples from five
month-old female TA2 mice (Group A), as well as 28 samples from mammary (Group B) and cancer tissues (Group
C) of spontaneous breast cancer-bearing TA2 mice, were subsequently used to detect the expression of decorin,
EGFR and cyclin D1 by real-time PCR and immunohistochemical methods.
Results: Several imprinted genes, oncogenes and tumor suppressor genes were differentially expressed between
normal mammary gland tissues and breast cancer tissues of TA2 mice. The imprinted gene decorin and the oncogene
EGFR were down-regulated in tumor tissues, while the oncogene cyclin D1 was up-regulated. Immunohistochemistry
showed that samples in Group A showed high decorin expression more frequently than those in Group B (P < 0.05).
More tissue samples in Group B than Group A were positive for nuclear EGFR, and tissue samples in Group B more
frequently showed high nuclear EGFR expression than those in Group A or Group C (P < 0.05). The labeling index for
cyclin D1 in Group C was significantly higher than in Group B. Mammary tissues of Group A expressed the highest level
of decorin mRNA (P < 0.05), and mammary tissues of Group B expressed the highest level of EGFR mRNA (P <0 . 0 5 ) ,
while cancer tissues expressed the highest level of cyclin D1 mRNA (P < 0.05).
Conclusions: The expression of decorin, EGFR and cyclin D1 in mammary epithelial cells changes with increasing
age. The abnormal expression of them may partly contribute to the genesis of spontaneous breast cancer in TA2
mice.
Background
The Tientsin Albino 2 (TA2) mouse is an inbred strain
originating from the Kunming strain. It has a high inci-
dence of spontaneous breast cancer without the need
for external inducers or carcinogens. The morbidity in
parous females is 84.1% within an average of 280 days
after birthing a litter [1-3]. Until now, the mechanism of
carcinogenesis has remained unclear. Gene expression
arrays are commonly used in cancer research to identify
differentially expressed candidate genes under two dif-
ferent conditions [4,5]. The Affymetrix expression array
is one of the most widely used commercially available
oligonucleotide arrays and can determine the gene
e x p r e s s i o ns t a t u so fv i r t u a l l yt h ec o m p l e t eg e n o m ea t
the mRNA level. * Correspondence: baocunsun@eyou.com
† Contributed equally
1Department of Pathology, Tianjin Cancer Hospital and Institute, Tianjin
Medical University, Tianjin 300060, China
Gu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:6
http://www.jeccr.com/content/29/1/6
© 2010 Gu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Genomic imprinting is an epigenetic process that
marks the parental origin of a subset of genes, resulting
in the silencing of specific alleles [6]. To date, more
than 70 imprinted genes have been described in the
mouse http://www.mgu.har.mrc.ac.uk/imprinting/
imprinting.html. Proteins encoded by these genes
include growth factors and components of the extracel-
lular matrix (ECM). Imprinted genes are involved in
several cellular processes and perform a variety of func-
tions, including cell cycle control, G-protein-coupled
receptor signaling, and intracellular signaling, thereby
influencing both pre- and postnatal growth and develop-
ment through endocrine/paracrine pathways[6]. More
recent data have shown that abnormal expression of
several imprinted genes including decorin can cause
tumorigenesis. Decorin is a maternally expressed
imprinted gene that belongs to the small leucine-rich
proteoglycan (SLRP) gene family and has been impli-
cated in the control of cell proliferation [7,8]. Reduced
expression of decorin facilitates tumorigenesis and cell
growth [9,10]. Decorin is a functional component of the
ECM, and is also considered to be a novel biological
ligand for EGFR, which is frequently expressed at ele-
vated levels in multiple cancers of epithelial origin.
Interactions between these factors can inhibit cell
growth during tissue remodeling and cancer develop-
ment [11]. In addition to serving as a ligand for EGFR,
decorin can bind to various forms of active TGF-b
through its core protein and can neutralize the activity
of TGF-b[12]. Abnormal expression of decorin has been
found in many tumors, including lymphoma and human
breast carcinoma [13,14].
In this study, gene expression profiles of normal mam-
mary glands and spontaneous breast cancer tissues from
TA2 mice were detected by Affymetrix Mouse Genome
430 2.0 Arrays for the first time. The expression data
were analyzed by the MAS5.0 [4], BGX[15], and Array2-
BIO[16] methods. Based on the candidate genes identi-
fied by expression profiling, we hypothesized that
abnormal expression of decorin, EGFR, and cyclin D1
might induce carcinogenesis of mammary gland epithe-
lial cells in TA2 mice.
Methods
Animals and Sampling
Female TA2 mice (five month-old TA2 mice and sponta-
neous breast cancer-bearing TA2 mice) were purchased
from the Experimental Animal Center of Tianjin Medical
University. The Animal Ethics Committee of National
Research Institute for Family Planning Beijing approved
the animal experimentation protocols and all animal
experiments were performed according to guidelines
(Guidelines for the Care and Use of Laboratory Animals)
established by the Chinese Council on Animal Care.
A total of 12 five month-old mice and 28 cancer-bear-
ing mice were used in this study. As for the 28 cancer-
bearing mice, spontaneous breast cancer was found with
an average of 307 days after birth (213 days to 408
days). After euthanasia, mammary glands and sponta-
neous breast cancer tissues were collected from each
cancer-bearing animal. Two abdominal mammary glands
were collected from the five month-old mice (Group A).
One was immediately frozen in liquid nitrogen and
stored at -70°C, and the other was fixed in 4% formalin
and embedded in paraffin. For cancer-bearing mice,
spontaneous breast cancer tissues (Group C) and nor-
mal mammary glands located on the side opposite to
the tumor (Group B) were collected. Portions of the
tumor tissues and one of the normal mammary glands
were immediately frozen in liquid nitrogen and stored at
-70°C; the remaining tumor tissues and mammary
glands were routinely fixed in 4% formalin and
embedded in paraffin.
RNA Extraction
Total RNA was extracted from frozen tissue using Tri-
zol reagent (Invitrogen, Paisley, UK) and isolated using
t h eR N e a s ye x t r a c t i o np r o t o col from Qiagen (Valencia,
CA, USA). The integrity of total RNA for each sample
was determined by denaturing gel electrophoresis (1.2%
methyl aldehyde running gel), and the purity of RNA
was checked by spectrophotometry. The O.D. 260/280
nm ratio was between 2.05-2.15 for each RNA sample.
Microarray hybridization and data analysis
Total RNA from six samples harvested from three mice
(three samples each for Groups B and C) was used for
microarray hybridization. Microarray analysis was con-
ducted using Affymetrix (Santa Clara, CA) Mouse Gen-
ome 430 2.0 Arrays (over 39,000 transcripts and
variants from over 34,000 well characterized mouse
genes). The procedure was conducted according to the
manufacturer’s instructions (Affymetrix) using T7-(dT)
24-oligonucleotide primers for cDNA synthesis (Affyme-
trix), the cDNA Cleanup Module (Affymetrix) for purifi-
cation and the IVT Labeling Kit (Affymetrix) for making
biotin-labeled cRNA. Clean-up of cRNA using RNeasy
columns (Qiagen, Crawley, Sussex, UK) was performed
to remove unincorporated ribonucleotides prior to
quantification by spectrophotometry. The cRNA was
fragmented by metal-induced hydrolysis at 94°C for 35
min in a 40 mM final concentration Tris buffer. The
length of the fragmented cRNA was between 25 bp and
200 bp. Adequacy of cRNA fragmentation was deter-
mined by 1.2% denaturing gel electrophoresis, and a
hybridization control was prepared in hybridization buf-
fer. The Affymetrix GeneChip system was used for
hybridization, staining, and imaging of the arrays
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zation cocktails were hybridized to Mouse Genome 430
2.0 Arrays, after which the arrays were washed using a
Fluidics Station 450 (FS450, Affymetrix) and then
scanned using a Scanner 3000 7G 4C (Affymetrix).
Microarray Suite 5.0 software (MAS5.0, Affymetrix) was
used to process images and estimate transcript expres-
sion levels. The expression data were analyzed by
MAS5.0, BGX and Arrary2BIO methods.
Real-time PCR
The relative expression levels of decorin, EGFR, cyclin
D1 and PCNA were determined by quantitative PCR
using SYBR Premix Ex Taq(TaKaRa Code: DRR041A)
purchased from TaKaRa Biotechnology (Dalian) Co., Ltd
with b-actin as a reference (TaKaRa Code: D3751). Sam-
ples were run in separate tubes on an ABI Prism 7500
Sequence Detection System according to the manufac-
turer’s suggested protocols. In brief, the 50 μl samples
were treated at 50°C for 2 min and 95°C for 10 s fol-
lowed by 40 cycles of 95°C for 5 s and 64.2°C (for EGFR
and PCNA), 65.0°C (for cyclin D1), or 60°C (for decorin)
for 33 s. Relative quantitation using the comparative CT
method was performed for each sample. Primers were
synthesized by TaKaRa Biotechnology (Dalian) Co., Ltd.
with the following sequences: decorin (GenBank acces-
sion no. NM_007833), forward 5’-TGATGCACC-
CAGCCTGAAAG-3’,r e v e r s e5 ’-
TCCATAACGGTGATGCTGTTGAA-3’;E G F R( G e n -
Bank accession no. NM_207655), forward 5’-
AGGACTGGGCAATCTGTTGGA-3’, reverse 5’-GAA-
GATCGAAGACCTGGTGCTGTAA-3’;P C N A( G e n -
Bank accession no. NM_011045), forward5’-
GGACTTAGATGTGGAGCAACTTGGA-3’; reverse 5’-
AATTCACCCGACGGCATCTTTA-3’; cyclin D1 (Gen-
Bank accession no. NM_007631), forward 5’-AGT-
CAGGGCACCTGGATTGTTC-3’,r e v e r s e5 ’-
AACAGATTAAATGATGCACCGGAGA-3’.E x p e r i -
ments were performed in triplicate for each sample.
Immunohistochemistry
Formalin-fixed and paraffin-embedded mammary gland
and spontaneous breast cancer specimens were used for
immunohistochemical detection of decorin, EGFR,
cyclin D1 and PCNA. Sections 4 μmi nt h i c k n e s sw e r e
deparaffinized and rehydrated with xylene and graded
alcohol solutions. After washing with PBS, endogenous
peroxidase activity was quenched by 3% hydrogen per-
oxide, and sections were boiled in 10 mM citrate buffer
(pH 6.0) for 3 min in an autoclave sterilizer followed by
cooling at room temperature for more than 20 min.
After rinsing with PBS, sections were incubated with
primary antibodies (1:100 dilution in antibody diluent,
Zhongshan Goldbridge Biotechnology CO., Ltd, Beijing,
China) for 18 hr at 4°C. Sections were stained with anti-
decorin (SC-73896, Santa Cruz Biotechnology, Inc),
anti-EGFR (BA0843, Boster Biological Technology, Ltd,
Wuhan, China), anti-cyclin D1 (Cat. #RM-9104-S1, Neo-
marker Labvision, USA), or anti-PCNA (BM0104, Boster
Biological Technology, Ltd,W u h a n ,C h i n a )a n t i b o d i e s .
After rinsing with PBS, sections were incubated with
PV6001 or PV6002 (Zhongshan Goldbridge Biotechnol-
ogy CO., Ltd, Beijing, China) for 30 min at 37°C and
stained with DAB (AR1022, Boster Biological Technol-
ogy, Ltd, Wuhan, China) for 1 to 2 min. The slides were
counterstained with hematoxylin, dehydrated with etha-
nol, cleared with xylene, and mounted in neutral gum.
Control sections were incubated with PBS instead of a
primary antibody. All slides were analyzed by two inde-
pendent observers.
Immunohistochemical staining evaluation
For cyclin D1 and PCNA, only the percentage of immu-
noreactive epithelial cells and breast cancer cells was
considered (labeling index). Briefly, the areas of high
percentage of cyclin D1 positive cells (’hot spots’)w e r e
identified at low magnification (×10 ocular and ×10
objective) as the “hot spots”. Then, ten hot spot areas
per section were selected and were observed at a higher
magnification (×10 ocular and ×40 objective, high power
field) with a grid (OLYMPUS 100×) in the ocular lens.
All epithelial cells or cancer cells and immunohisto-
chemistry positive cells in the grid were counted in
every high power field, respectively. The mean percen-
tage of positive cells (labeling index) was used to evalu-
ate the expression of the protein in a section. For EGFR,
both the percentage and intensity of EGFR-positive
epithelial cells and breast cancer cells were considered
in a semi-quantitative assessment [17]. The percentage
of EGFR-positive cells was scored as 0 (0% positive
cells), 1 (1-25% positive cells), 2 (26-50% positive cells),
3 (50-75% positive cells), or 4 (>75% positive cells). The
intensity of EGFR immunostaining was also scored as 0
(negative), 1 (weak), 2 (intermediate) and 3 (strong).
T h ei n t e n s i t ys c o r e( 0 - 3 )w a sm u l t i p l i e db yt h ep e r c e n -
tage score (0-4) and a final score was assigned 0 (nega-
tive), 1-4 (weak expression), 5-8 (moderate expression),
and 8-12 (strong expression). Samples with scores of 0-4
were considered to show low expression, while those
with scores of 5-12 were considered to show high
expression. For decorin, the percentage of decorin-posi-
tive cells or decorin-positive areas located around the
terminal duct and gland alveolus was scored as 0 (0%
positive cells or substance), 1 (1-25% terminal duct and
gland alveolus), 2 (26-50% terminal duct and gland
alveolus), or 3 (>50% terminal duct and gland alveolus),
and samples with scores of 3 were considered to show
high expression. In tumor tissues, the distribution of
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recorded.
Statistical Analysis
A l ld a t aw e r ea n a l y z e du s i n gS P S Ss t a t i s t i c a ls o f t w a r e
(version 11.5 for Windows). The Kruskal-Wallis and
Mann-Whitney tests were used to evaluate statistical
significance of differences, and the Spearman rank test
was used to assess the correlation between the expres-
sion of EGFR and cyclin D1 or PCNA. Differences were
considered statistically significant at P < 0.05.
Results
Differentially expressed imprinted genes and oncogenes
between normal mammary glands and spontaneous
breast cancer tissues
Expression profiles of spontaneous breast cancer and
matched normal mammary glands were obtained using
the Affymetrix GeneChip Mouse430 2.0 oligonucleotide
array. In total, 260 differentially expressed candidate
genes (data not shown) were detected by all three analy-
sis methods (MAS5.0, BGX, Array2BIO). These genes
included five imprinted genes and seven oncogenes or
tumor suppressor genes (Table 1). Of these genes, the
imprinted gene decorin and the oncogene EGFR were
down-regulated in tumor tissues as compared to normal
mammary gland tissues, and the oncogene cyclin D1
was up-regulated in tumor tissues.
Expression of decorin in normal mammary glands and
spontaneous breast cancer tissues
To localize decorin protein, immunohistochemical ana-
lysis was performed using normal mammary gland and
spontaneous breast cancer samples. Decorin was
expressed in normal mammary gland tissues of five
month-old TA2 mice (Group A) and breast cancer-bear-
ing TA2 mice (Group B), as well as in breast cancer tis-
sues from TA2 mice (Group C). It was mainly present
in the ECM and expressed by mesenchymal cells, such
as fibroblasts and some inflammatory cells (Fig 1A). In
normal mammary gland tissue samples (Group B), weak
decorin staining was present in the ECM, with stronger
staining around the terminal duct and gland alveolus,
while the epithelial cells were devoid of decorin staining.
In contrast, tissues of Group A showed strong decorin
staining in the ECM. The strongest decorin-positive
structures were located around the terminal duct and
gland alveolus (Fig 1B, C). Group A showed a signifi-
cantly higher percentage of cells highly expressing dec-
orin (high expression in 50%) than Group B (high
expression in 17.86%). Tissues in Group B showed a sig-
nificant decrease in the occurrence of high decorin pro-
tein expression (high expression in 17.86%) compared to
Group A (high expression in 50%) (c
2 = 4.35;P = 0.037).
This finding suggests that the mammary glands of
young mice expressed higher levels of decorin than
those of spontaneous cancer-bearing mice. In Group C,
tumor cells exhibited no decorin immunoreactivity, and
decorin was only expressed by some mesenchymal cells,
with the strongest staining observed in the ECM at the
border of the tumor (Fig 1D).
Real-time PCR was performed to evaluate the expres-
sion level of decorin mRNA in mammary gland tissues
and tumor tissue samples. Normal mammary glands
(Group A) expressed the highest level of decorin mRNA
among the three groups, and tumor tissues (Group C)
expressed the lowest level (Table 2).
Expression of EGFR in normal mammary glands and
spontaneous breast cancer tissues
EGFR was expressed by terminal duct epithelial cells,
gland alveolus cells and tumor cells, as well as some
mesenchymal cells. In Group A, EGFR was mainly
expressed by epithelial cells and localized to the cyto-
plasm (Fig 2A). In spontaneous breast cancer-bearing
mice, stronger EGFR staining was observed in mammary
gland samples when compared to tumor samples, and
nuclear translocation was observed in both tissue types
(Fig 2B, C, D). EGFR-expressing samples and EGFR
nuclear translocation were also more often observed in
Group B than in Group A (respectively: c
2 =7 . 5 6 ,P <
0.01; c
2 =2 0 . 4 9 ,P < 0.01). High levels of EGFR staining
were more often observed in Group B than in Group C
(c
2 =4 . 1 4 ;P < 0.05, Table 3); this pattern was sup-
ported by real-time PCR data. Normal mammary glands
(Group A) showed the lowest level of EGFR mRNA
expression, while mammary glands from tumor-bearing
mice (Group B) showed the highest expression level
(Table 2).
Expression of cyclin D1 and PCNA in normal mammary
glands and spontaneous breast cancer tissues
Cyclin D1 and PCNA were expressed by terminal duct
epithelial cells, gland alveolus cells and tumor cells (Fig
3A-3D, Fig 4A-4C). Some mesenchymal cells also
showed cyclin D1 and PCNA staining. In five month-old
mice, cyclin D1 staining was observed occasionally in
anestric epithelial cells. In mammary gland tissue sam-
ples of tumor-bearing mice, most epithelial cells were
negative for cyclin D1 staining and several “hot spots
areas” (areas with high expression of cyclin D1) were
observed. In general, one hot spot area limited to one
“mammary gland lobula” which contained several closely
distributed terminal duct and gland alveolus. In hot spot
areas, the cyclin D1 labeling index in Group C was
higher than in Group B (22.33 ± 17.25 vs. 12.25 ± 7.19,
Z = -2.25, P < 0.05). In Groups B and C, the cyclin D1
labeling index was higher in samples with nuclear EGFR
Gu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:6
http://www.jeccr.com/content/29/1/6
Page 4 of 10expression than in samples without nuclear EGFR
expression (Z = -2.28, P < 0.05, Group B; Z = -2.07, P <
0.05, Group C, respectively); results are shown in Table
4. Most of the “hot spot” cyclin D1 areas also demon-
strate a “hot spot” of nuclear localized EGFR. A positive
correlation was found between the cyclin D1 labeling
index and the expression level of nuclear EGFR in
Groups B and C (rs = 0.723, 0.474, P < 0.05), but no
correlation was established between nuclear EGFR
expression and the PCNA labeling index. These results
suggest that nuclear EGFR could be an upstream effec-
tor of cyclin D1 expression. Furthermore, we analyzed
the expression of cyclin D1 and PCNA mRNA (Table
3), and found that cyclin D1 mRNA was progressively
upregulated in the following relative magnitudes: Group
A < Group B < Group C. Because the mammary gland
tissues used for immunohistochemical staining and real-
time PCR were independent samples, we could not cor-
relate the expression of nuclear EGFR and the expres-
sion levels of cyclin D1 mRNA. However, a trend
(tendency) of positive correlation was established
between the expression level of nuclear EGFR and the
expression level of cyclin D1 mRNA for tumor tissue
samples that did not reach significance (rs =0 . 8 8 3 ,P =
0.059). These findings also suggest that nuclear EGFR
might partly regulate the expression of cyclin D1.
Discussion
Breast cancer is one of the most common malignant
tumors in adult females and develops as a result of
altered expression of multiple genes and abnormal cellu-
lar pathways. In recent years, accumulating data has
shown that alterations of the stromal compartment can
also influence tumor cell behavior through paracrine
growth factor pathways[9]. Proteoglycans are the main
constituents of the ECM, and their synthesis and degra-
dation are regulated by many effectors that control the
development and function of the mammary gland. We
hypothesized that alterations in the composition and
architecture of the ECM could promote carcinogenesis
of breast epithelial cells. To test this hypothesis, we used
tissue samples taken from TA2 mice. Gene expression
Table 1 Differentially expressed candidate imprinted genes, oncogenes and tumor suppressing genes identified by
MAS5.0, Array2BIO and BGX methods
Gene
symbol
Description Genbank Biological process Biological function
Imprinted gene
Dcn Decorin AV321547 —— protein binding
Igf2 Insulin like
growth factor
2
NM010514 regulation of cell cycle; cell proliferation receptor binding; hormone activity; protein
binding; growth factor activity
Mest Mesoderm
specific
transcript
AW555393 Proteolysis Catalytic activity; aminopeptidase activity
Ndn Necdin BB074430 Regulation of cell growth; nerve growth factor receptor
signaling pathway; transcription; neuron migration
DNA binding; protein binding; gamma-tubulin
binding
Peg3 Paternally
expressed 3
BB305002 apoptosis Nucleic acid binding; metal ion binding
Oncogenes or tumor suppressor genes
Bcl11a B-cell CLL/
lymphoma
11A
BF731393 transcription; B cell and T cell differentiation nucleic acid binding; zinc ion binding;
transcription co-repressor activity
Ccnd1 cyclin D1 BB452046 Regulation of cell cycle; protein amino acid phosphorylation;
fat cell differentiation; cell division
protein kinase activity; protein binding
Cdh11 Cadherin 11 BG072720 Cell adhesion Calcium ion binding; protein binding
Egfr Epidermal
growth factor
receptor
BB409522 Cell morphogenesis; signal transduction; cell proliferation;
regulation of cell migration; cell adhesion; regulation of
peptidyl-tyrosine phosphorylation
Nucleotide binding; kinase activity; iron ion
binding; ATP binding; protein binding; signal
transducer activity; receptor activity; transferase
activity; actin filament binding
Fcgr2b Fc receptor,
IgG, low
affinity IIb
BB530063 Negative regulation of type I hypersensitivity; immune
response; signal transduction; regulation of B cell
proliferation; mast cell activation; regulation of phagocytosis
Receptor activity; protein binding; IgG binding
Gpc3 Gypican 3 BM198842 Ureteric bud branching; regulation of cell proliferation;
regulation of BMP signaling pathway; regulation of growth
GPI anchor binding
Vav3 Vav 3
oncogene
BM224051 Vesicle fusion; signal transduction; regulation of cell adhesion;
cell migration; intracellular signaling cascade; cell projection
biogenesis; regulation of PI3 kinase activity; integrin-mediated
signaling pathway
diacylglycerol binding; EGFR binding; metal ion
binding; exchange factor activity
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and tumor suppressor genes were differentially
expressed between normal mammary glands and sponta-
neous breast cancer tissues. Some of these genes
encoded stromal constituents such as versican and dec-
orin. Decorin is synthesized by the majority of mesench-
ymal cells [18]. However, it also interacts with a variety
of other ECM components and can affect cell growth. It
has been shown that decorin functionally inactivates the
ErbB2 protein in breast carcinoma cells [18], leading to
growth suppression and cytodifferentiation of mammary
carcinoma cells. Reduced expression of decorin may
facilitate cell growth, tumorigenesis and metastasis[9,19].
In human breast cancer tissues, decorin levels were
decreased 2-5-fold when compared to normal breast tis-
sue[14]. Treatment with decorin protein reduced pri-
mary tumor growth by 70% and eliminated observable
metastasis in an orthotopic mammary carcinoma animal
model injected with a metastatic breast cancer cell line.
Adenoviral overexpression of decorin caused primary
tumor retardation of 70%, in addition to greatly redu-
cing the observation of metastasis [20]. The expression
arrays revealed that decorin was down-regulated in
tumor tissues, so we speculate that loss of decorin
Figure 1 Expression of decorin in mammary glands and spontaneous breast cancer tissues from TA2 mice. 1A, 1B, Decorin-positive
structures were located around the terminal duct and gland alveolus in five-month-old TA2 mice and was mainly expressed by mesenchymal
cells (IHC, 200×). 1C, Decorin-positive structures were located around the terminal duct and gland alveolus from tumor-bearing TA2 mice (IHC,
200×). The mammary glands of young mice expressed higher levels of decorin than those of spontaneous cancer-bearing mice. 1D, Decorin-
positive structures were present in the ECM of tumor tissues (IHC, 200×).
Table 2 Expression levels of decorin, EGFR, cyclin D1 and
PCNA mRNA in mammary glands and spontaneous
breast cancer tissues of TA2 mice
Group Decorin EGFR Cyclin D1 PCNA
Group A 0.95 ± 0.25 0.02 ± 0.01 0.04 ± 0.01 0.14 ± 0.10
Group B 0.27 ± 0.20* 0.05 ± 0.02* 0.13 ± 0.08* 0.38 ± 0.24*
Group C 0.13 ± 0.10
# 0.03 ± 0.01
# 0.42 ± 0.22
# 0.17 ± 0.10
#
*: compared with Group A, P <0 . 0 5 ;
#: compared with Group B, P < 0.05
Group A: normal mammary glands from five-month-old TA2 mice; Group B:
normal mammary glands from spontaneous breast cancer-bearing TA2 mice;
Group C: spontaneous breast cancer tissue from TA2 mice.
Table 3 EGFR staining in normal mammary glands and
tumor tissues from TA2 mice(expressed as a percentage
of samples with positive staining)
n Positive
expression
Nuclear
translocation
High expression
level
Group A 12 33.33(4/12) 0.00(0/12) 0.00(0/12)
Group B 28 78.57(22/28)
# 53.57(15/28)
# 42.86(12/28)*
Group C 28 64.29(18/28)
# 39.28(11/28)
# 17.86(5/28)
#: compared with Group A, P < 0.05; *: compared with Group C, P < 0.05
Group A: normal mammary glands from five month-old TA2 mice; Group B:
normal mammary glands from spontaneous breast cancer-bearing TA2 mice;
Group C: spontaneous breast cancer tissue from TA2 mice.
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mammary epithelial cells. As a component of the ECM,
decorin can bind several growth factors and their recep-
tors, such as EGFR. After binding EGFR, decorin can
inhibit cell proliferation by up-regulating the expression
of p21.
EGFR on the cell surface is t h o u g h tt op l a yap i v o t a l
role in cell proliferation, cell migration, and cell survival,
but Marti et al.[21] also reported a nuclear distribution
for EGFR, now called “nuclear EGFR,” in primary adre-
nocortical carcinomas more than a decade ago. High
levels of nuclear EGFR have subsequently been reported
in many tumors, including those of the human breast,
thyroid and cervix [22,23]. Thus two different signaling
pathways, cytoplasmic/traditional and nuclear, have
been identified. The cytoplasmic EGFR pathway often
leads to tumorigenesis, tumor proliferation, metastasis,
chemoresistance and radioresistance through the activa-
tion of Ras, PI-3K and STATs. The nuclear EGFR sig-
naling pathway can escape the traditional transduction
cascades and has different functions that depend on
down-stream signaling molecules. Nuclear EGFR inter-
acts with the DNA-binding transcription factors E2F1
and STAT3, and can accelerate G1/S cell cycle progres-
sion by up-regulating the expression of cyclin D1 and B-
Myb. Cyclin D1 is a well-known oncogene whose over-
expression is found in many cancers and is related to
tumor progression and metastasis. Consistent with this
mechanism, nuclear accumulation of EGFR is also asso-
ciated with increased cell proliferation [22]. Increased
expression of nuclear EGFR has been linked to poor
clinical outcomes in patients with breast carcinoma [24]
Figure 2 Expression of EGFR in mammary glands and spontaneous breast cancer tissues from TA2 mice. 2A, EGFR staining could be
observed occasionally in epithelial cells in mammary gland tissues from five-month-old TA2 mice (IHC, 200×). 2B and 2C, EGFR staining was
localized to both the cytoplasm and nucleus in mammary gland tissues from spontaneous breast cancer-bearing TA2 mice (IHC, 200×). 2D,
Nuclear EGFR was also present in spontaneous breast cancer tissues from TA2 mice (IHC, 200×). Mammary gland tissues and tumor tissues from
cancer-bearing TA2 mice expressed higher levels of EGFR than those of mammary gland tissues of five-month-old TA2 mice.
Table 4 Cyclin D1 and PCNA labeling index of normal
mammary glands and cancer tissues from spontaneous
breast cancer -bearing TA2 mice (%)
n Cyclin D1 PCNA
Group B
Nucleus EGFR (+) 15 15.15 ± 5.16* 37.81 ± 12.77
Nucleus EGFR (-) 13 8.77 ± 7.95 33.71 ± 15.78
Group C
Nucleus EGFR (+) 11 31.17 ± 12.50* 44.9212.01
Nucleus EGFR (-) 17 18.54 ± 17.98 33.9413.92
*:compared to samples without nuclear EGFR expression, P < 0.05
Group B: normal mammary glands from spontaneous breast cancer-bearing
TA2 mice; Group C: spontaneous breast cancer tissue from TA2 mice.
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Page 7 of 10and oropharyngeal squamous cell carcinoma [25]. In the
present study, we found that EGFR was located on the
cell surface of mammary gland epithelial cells in five-
month-old TA2 mice, while no nuclear EGFR was
detected. In contrast, nuclear EGFR was detected in
epithelial cells from normal mammary glands removed
from spontaneous breast cancer-bearing TA2 mice as
well as in breast cancer cells from those animals. In
order to confirm the function of nuclear EGFR, we
detected the expression of cyclin D1. A positive correla-
tion between nuclear EGFR and cyclin D1 expression
was observed both in mammary gland samples and
breast cancer samples of cancer-bearing TA2 mice. The
same result has also been observed in a cohort of breast
carcinoma patients[24]. Our results suggest that nuclear
translocation of EGFR may occur with increasing age,
and that nuclear EGFR can promote the expression of
cyclin D1, leading to a high proliferation index in
mammary epithelial cells. Proliferating cell nuclear anti-
gen (PCNA), the maestro of the replication fork, is a
cofactor of DNA polymerases [26,27]. PCNA is now one
of the most commonly used molecules to detect the
proliferation index of tumor cells. Our results indicated
that the mammary epithelial cells from cancer-bearing
TA2 mice had a higher proliferation index (PCNA label-
ing index) than those of the five-month-old TA2 mice,
and this was further confirmed by real-time PCR. In
order to know whether nuclear EGFR could affect the
expression of PCNA we also detected PCNA by immu-
nohistochemical staining and real-time PCR. No correla-
tion was found between PCNA and EGFR expression.
Our results confirm that nuclear EGFR can indirectly
up-regulate the expression of cyclin D1.
In the present study, expression profiles data showed
that EGFR expression was down-regulated in cancer tis-
sues compared with that of the matched mammary
Figure 3 Expression of cyclin D1 in mammary glands and spontaneous breast cancer tissues from TA2 mice. 3A, Cyclin D1 staining
could be observed occasionally in epithelial cells from five month-old TA2 mice (IHC, 200×). 3B, Cyclin D1 staining was present in the nuclei of
epithelial cells in mammary gland tissues of spontaneous breast cancer-bearing TA2 mice (IHC, 200×). 3C, Cyclin D1 staining was present in the
nuclei of hyperplastic epithelial cells of spontaneous breast cancer-bearing TA2 mice (IHC, 200×). 3D, Cyclin D1 staining was also present in
spontaneous breast cancer tissues of TA2 mice (IHC, 200×). The Labeling Index of cyclin D1 increased apparently from Group A to Group C.
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Page 8 of 10glands, in contrast to results previously reported for
human breast cancer. In order to confirm our findings,
we detected EGFR expression by real-time PCR and
immunohistochemical staining. The results of real-time
PCR and immunohistochemical staining were consistent
with those of the gene arrays. As we know, EGFR is one
of the prognostic factors and therapeutic targets for
human breast cancers[22]. According to our results,
EGFR may have different effect on the progression of
breast cancer of TA2 mice and human beings. For TA2
mice, high level of EGFR played an important role in
the carcinogenesis of its mammary gland epithelial cells,
which needs further exploration.
Conclusions
In briefly, our data suggest that the expression of decorin,
EGFR and cyclin D1 in mammary epithelial cells changes
with increasing age. Anestric mammary epithelial cells
from five-month-old mice expressed low levels of EGFR.
The kinase activity of this EGFR may have been attenu-
ated in part by decorin. With increased age, decreased
expression of decorin, increased expression of EGFR,
especially nuclear EGFR, and increased expression of
cyclin D1 may be the crucial alterations causing increased
proliferation of mammary epithelial cells and these may
partly conduce to the carcinogenesis of mammary gland
epithelial cell of TA2 mice, which needs further studies.
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